Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inovio Pharmaceuticals, Inc. (INO : NSDQ)
 
 • Company Description   
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Number of Employees: 262

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.69 Daily Weekly Monthly
20 Day Moving Average: 5,337,062 shares
Shares Outstanding: 209.40 (millions)
Market Capitalization: $1,819.68 (millions)
Beta: 0.66
52 Week High: $33.79
52 Week Low: $5.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.91% 16.64%
12 Week -6.36% -12.30%
Year To Date -1.81% -13.05%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
660 WEST GERMANTOWN PIKE SUITE 110
-
SAN DIEGO,CA 19462
USA
ph: 267-440-4200
fax: 267-440-4242
investor.relations@inovio.com http://www.inovio.com
 
 • General Corporate Information   
Officers
J. Joseph Kim - Chief Executive Officer and President
Simon X. Benito - Chairman
Peter Kies - Chief Financial Officer
Ann Miller - Director
Jay Shepard - Director

Peer Information
Inovio Pharmaceuticals, Inc. (CORR.)
Inovio Pharmaceuticals, Inc. (RSPI)
Inovio Pharmaceuticals, Inc. (CGXP)
Inovio Pharmaceuticals, Inc. (BGEN)
Inovio Pharmaceuticals, Inc. (GTBP)
Inovio Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45773H201
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/09/21
Share - Related Items
Shares Outstanding: 209.40
Most Recent Split Date: 6.00 (0.25:1)
Beta: 0.66
Market Capitalization: $1,819.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.07 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.11
Price/Cash Flow: -
Price / Sales: 281.90
EPS Growth
vs. Year Ago Period: -3.85%
vs. Previous Quarter: -92.86%
Sales Growth
vs. Year Ago Period: -72.04%
vs. Previous Quarter: -93.35%
ROE
03/31/21 - -39.16
12/31/20 - -44.92
09/30/20 - -78.17
ROA
03/31/21 - -29.30
12/31/20 - -29.59
09/30/20 - -40.33
Current Ratio
03/31/21 - 14.17
12/31/20 - 11.30
09/30/20 - 9.14
Quick Ratio
03/31/21 - 14.17
12/31/20 - 11.30
09/30/20 - 9.14
Operating Margin
03/31/21 - -2,355.40
12/31/20 - -1,756.58
09/30/20 - -6,516.92
Net Margin
03/31/21 - -2,916.64
12/31/20 - -2,245.42
09/30/20 - -8,518.10
Pre-Tax Margin
03/31/21 - -2,846.21
12/31/20 - -2,197.95
09/30/20 - -8,469.67
Book Value
03/31/21 - 2.79
12/31/20 - 2.47
09/30/20 - 1.93
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - 0.02
12/31/20 - 0.04
09/30/20 - 0.17
Debt-to-Capital
03/31/21 - 2.36
12/31/20 - 3.89
09/30/20 - 14.22
 

Powered by Zacks Investment Research ©